Clinical Trial Update: Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Ig NextGen 10% for idiopathic thrombocytopenic purpura (ITP) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• Ig NextGen 10%

Snippet

Sponsor: CSL Limited | Conditions: Idiopathic Thrombocytopenic Purpura (ITP) | Phase 3 | Status: COMPLETED